October 20, 2026
Jemperli’s FDA clearance shifts care, but the cleaner options trade may sit in testing and robotic surgery stocks the approval quietly pressures.
Yesterday the FDA granted accelerated approval to GSK’s Jemperli (dostarlimab) as the first and only immunotherapy for adults with stage II or III MSI-H/dMMR locally advanced rectal cancer, nearly four months ahead of its February 2027 FDA goal date under priority review. The decision was built on AZUR-1 data: investigator-assessed results showed 68% of evaluable patients achieved sustained clinical complete responses at 12 months, and with a median follow-up of 26.3 months, none of the patients with sustained complete response, complete response, or near complete response experienced disease progression.
Elon Musk Just Did Something He’s Never Done Before
This February, Elon spent millions to send a message to 125 million Americans. Most people ignored it. But Wall Street veteran Whitney Tilson couldn’t stop thinking about it, and says what Elon was really saying explains everything about what’s unfolding in America’s economy right now.
That is a striking outcome. 110 of 154 treated patients had Jemperli alone, with no surgery, chemotherapy, or radiation, and no disease progression. The drug targets a biomarker-defined subset that accounts for roughly 5% to 10% of rectal cancers. Standard of care for that population has historically meant chemoradiation followed by surgery, procedures that can leave lasting bowel, urinary, and sexual side effects.
The science is real. So is the regulatory event. The options question is whether any tradable edge remains in GSK itself, and the honest answer is no. The approval arrived nearly four months early; the FDA decision had been penciled in for February 2027 under priority review. Early approvals compress the timeline that options premiums were pricing. Whatever vol had been built into GSK into the February window is now resolved. GSK reports Q3 2026 results on October 28, but an RBC Capital Markets note last week said Q3 revenue and EPS should be broadly in line, with HIV strength partly offsetting vaccine headwinds. That is not a catalyst that justifies paying elevated premium.
Where the Edge Actually Lives
The more interesting options situation is downstream. The Jemperli label requires biomarker confirmation: patients must have their tumor’s MSI-H or dMMR status confirmed with an FDA-authorized test for solid tumors before starting treatment. Every eligible patient goes through a molecular diagnostic before their first infusion. That is a structural volume driver for Exact Sciences (EXAS), which has been building colorectal diagnostic capacity aggressively. In July 2025, Exact Sciences announced Medicare coverage through MolDX for its Oncodetect molecular residual disease test, covering serial use in patients with stage II, III, and resectable stage IV colorectal cancer in the adjuvant and recurrence monitoring settings over a five-year period. An expanding immunotherapy-first treatment paradigm in rectal cancer could accelerate demand for testing, even if the exact mix shifts between upfront biomarker workups and longer-term monitoring.
5 Little-Known Stocks Behind Today’s Defense Tech Shift
Behind the headlines, a major transformation is underway.
Modern warfare is being driven by AI, autonomous systems, and next generation technology. A handful of lesser known companies are helping power this shift.
This report uncovers five stocks quietly playing a critical role in the future of defense.
The disruption runs the other direction for Intuitive Surgical (ISRG). Robotic colorectal surgery has been described in the clinical literature as a safe and effective minimally invasive approach, particularly in rectal cancer surgery, and Intuitive has been building that market for years. In its Q2 2026 earnings release, Intuitive said worldwide procedures (da Vinci and Ion combined) grew approximately 16% year over year, with da Vinci procedures up about 15%. A subset of rectal cancer patients now skipping surgery entirely does not collapse that growth, but it introduces a ceiling effect on procedure volume in precisely the specialty where Intuitive has emphasized clinical differentiation.
The Options Thesis
EXAS is the cleaner long. The biomarker testing mandate is not a soft tailwind; it is a required step before treatment. With the stock trading around a market cap near $10.4 billion and a pipeline that now includes MRD monitoring for colorectal cancer, there is a credible case that approval-driven testing volumes remain underappreciated in the next two to three quarters.
A bull call spread on EXAS, buying a near-the-money call and selling one strike higher into the next earnings window, caps premium outlay while capturing the scenario where testing volumes accelerate faster than current estimates reflect. Keep position size modest given EXAS’s history of volatile moves around results.
One idea. Backed by the analysts.
Join 130,000+ self-directed investors who get one trade idea a day, sourced from top Wall Street analysts and explained in plain English. Free, and a five-minute read.
On ISRG, the thesis is subtler. A widely circulated Wall Street summary this week pointed to three analysts flagging $500 price targets, including Oppenheimer’s August upgrade to Outperform with a $500 target. That kind of consensus leaves limited margin for a softening surgical volume story. A defined-risk bear put spread on ISRG, sized small, is an inexpensive way to express the view that robotic rectal surgery adoption faces a structural headwind that is not yet reflected in the prevailing tone of analyst models.
The Beast Verdict
The Jemperli approval is a genuine clinical milestone. But the approval itself is the event, not the catalyst. GSK options are a spent cartridge. The asymmetric opportunity, where a confirmed regulatory shift creates a new volume mandate that the market has not fully priced, belongs to the companies that sit earlier and later in the patient pathway: the diagnostic firms that must test every candidate, and the surgical robotics platform that benefits when those patients proceed to the operating room, and faces pressure when they increasingly do not. Watch EXAS testing volumes in the next two quarterly readouts. That is where the confirmation, or the miss, will surface first.
